AL-S Pharma Reports AP-101 Phase 2 Weight Data, Outlines Phase 3 Trial
AL-S Pharma reported new Phase 2 weight data for AP-101 and outlined a Phase 3 clinical trial in ALS at the 2026 NEALS Annual Meeting.
Story updates
10:08:09 AM UTC
SquawkNews
AL-S Pharma AG reported post-hoc Phase 2 data showing greater body-weight preservation with AP-101 vs placebo in ALS and outlined a NEALS-affiliated Phase 3 trial planned to start in 2027.Material DetailsContext by AI AnalystThis advances AL-S Pharma from Phase 2 signals toward a pivotal program, r…